Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.

Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development and commercialization of a pipeline of novel and targeted oncology therapies. Its product pipeline includes: Eflapegrastim, Poziotinib, and IGN002. The company was founded in December 1987 and is headquartered in Boston, MA.

Zellwerk GmbH develops and provides technologies for cell culture, biopharmaceutical processing and tissue engineering. Its products include Sponceram cell carriers and implant blanks as well as rotating bed bioreactors, Z RP Technology. The firm provides services for cultivation, recovery of glycoprotein products, cell formulations and colonized implant blanks for use in clinical research as well as isolation services regarding adult and embryonic stem cells. The company was founded in 1997 and is headquartered in Oberkrämer OT Eichstädt, Germany.

WindMIL Therapeutics translates novel insights in bone marrow immunology into life-saving cell therapies for cancer patients. The company leveraging its proprietary platform to develop a novel class of cell therapies called MILs (Marrow Infiltrating Lymphocytes) derived from memory T cells found in the bone marrow. WindMIL Therapeutics was established in 2015 and is based in Baltimore, MD.

Gaumard Scientific Co., Inc. is a private company headquartered in the United States that manufactures and markets simulators for health care education.\nThe company says this about itself: Gaumard Scientific is recognized by health care educators and students worldwide for its commitment to innovation with the development of the most advanced patient simulation technology. Gaumard designs and manufactures simulators at its global headquarters in Miami and markets them directly in the U.S. as well as through distributors in 70 countries. Gaumard's customer base includes militaries, emergency medical services, major teaching hospitals and nursing schools. Gaumard's product launch timeline reflects the company's unwavering commitment to innovation. In 2000, Gaumard launched the revolutionary family of NOELLE maternal and neonatal care simulators that changed the way training is conducted. In 2004, Gaumard pioneered the use of fully tetherless technology with the introduction of the family of HAL® simulators. In 2014, the company introduced VICTORIA®, its most advanced maternal and neonatal care simulator as part of the NOELLE family. In 2017, Gaumard introduced Super Tory, the first newborn simulator developed to meet the challenges of neonatal care specialists training in real environments.

Medigen Biotechnology was established at the end of 1999. The company adheres to the vision of “Innovation makes life better” and focuses on the development of new products in the two major areas of “hepatopathy” and “cancer” in Asia. Through years of hard work, Keya Biotech has gradually developed into a comprehensive biopharmaceutical group, and its business has covered: new drug clinical development, innovative biomedical research and development platform, molecular detection, cell culture vaccine technology, and scientific name drug production and marketing. And many other businesses.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany.

CheckMab Srl engages in research and development activities in the medical and molecular genetics field. It specializes in studies which aim to discover new therapies against tumors. The company was founded by Sergio Abrignani and Massimiliano Pagani in 2016 and is headquartered in Milan, Italy.

Cancer Research Ventures Ltd. engages in the business of research and experimental development on biotechnology. It provides medical products. The company is headquartered in London, the United Kingdom.

Actinium Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing therapies for life threatening diseases using its alpha particle immunotherapy platform and other related technologies. The company’s principal product candidates include Actimab-A, a Phase I/II clinical trial monoclonal antibody for the treatment of acute myeloid leukemia in elderly patients; and Iomab-B that has completed a Phase I/II design trial used to condition the bone marrow of patients by destroying blood cancer cells in their bone marrow. It also offers BC8-Y-90 and BC8-SA product candidates, which are in physician sponsored clinical phase I trials at the Fred Hutchinson Cancer Research Center. The company was founded in 2000 and is based in New York, New York.

Nanjing Winbo Biotechnology Co., Ltd., established on 2018-06-20, Business scope includes biotechnology research and development,Technical Services;Experimental equipment sales,Technical Services,Technology Promotion;medical instruments,Daily necessities,Office Supplies Sales;Self-operated and agent import and export business of various commodities and technologies(Except for commodities and technologies that the state restricts the company to operate or prohibits the import and export of).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Carbon Logic Biotechnology (Foshan) Co., Ltd., established on 2018-06-21, Business scope includes general items:Development of Human Gene Diagnosis and Therapy Technology;Medical Research and Experimental Development;Engineering and Technology Research and Experimental Development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:Drug Clinical Trial Services;Inspection and testing service;Technology Import and Export.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

TARIS Biomedical develops new therapies designed for the treatment of difficult-to-treat bladder diseases. The company's system is designed to continuously release drugs in the bladder over weeks to months and is deployed and retrieved using minimally-invasive, in-office procedures, enabling drug release to be tailored to match the needs of each disease.

Suzhou Yuna Medical Equipment Co., Ltd., established on 2013-07-25, Business scope includes medical devices,medical equipment,Testing Equipment,electronic product,Technology research and development of computer software and hardware,technology transfer,Technical consulting and sales of the above products;Production and sales of related medical non-hazardous chemical reagents and consumables;Self-operated and agent import and export business of various commodities and technologies(Except for commodities and technologies that the state restricts enterprises to operate or prohibits import and export).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments) Class III medical device business(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) Production of Class II Medical Devices(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) Production of Class I Medical Devices(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license) licensed items:Production of Class III Medical Devices(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results)

Genomic Health, Inc. (NASDAQ: GHDX) is a provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today. The company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of massive amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient's journey, from diagnosis to treatment selection and monitoring. The company is based in Redwood City, California, with European headquarters in Geneva, Switzerland.

BiPar Sciences Inc. is a Brisbane, CA based developer of PARP inhibitors as cancer therapies. BiPar's key experimental product is BSI-201, currently in mid-stage trials for advanced breast cancer, ovarian cancer and other tumors. BiPar has raised around $60 million in VC funding, from firms like [Domain Associates](/financial-organization/domain-associates), [Canaan Partners](/financial-organization/canaan-partners-3), [Vulcan Capital](/financial-organization/vulcan-capital), [PolyTechnos Venture Partners](/financial-organization/polytechnos-venture-partners), [Asset Management Company](/financial-organization/asset-management), and [Quantum Technology Partners](/financial-organization/quantum-technology-partners). It also has raised venture debt from [Lighthouse Capital Partners](/financial-organization/lighthouse-capital-partners). On April 15th, 2009, French drug maker [Sanofi-Aventis S.A.](/organization/sanofi-aventis-2) announced it was acquiring BiPar Sciences for up to $500 million.

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.